Cargando…

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies

Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells against haematological malignancy, solid tumors impose a far greater challenge to success. Largely, this stems from an inadequate capacity of CAR T-cells that can traffic and maintain function within a hostile mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Whilding, Lynsey M., Halim, Leena, Draper, Benjamin, Parente-Pereira, Ana C., Zabinski, Tomasz, Davies, David Marc, Maher, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563120/
https://www.ncbi.nlm.nih.gov/pubmed/31091832
http://dx.doi.org/10.3390/cancers11050674
_version_ 1783426478460895232
author Whilding, Lynsey M.
Halim, Leena
Draper, Benjamin
Parente-Pereira, Ana C.
Zabinski, Tomasz
Davies, David Marc
Maher, John
author_facet Whilding, Lynsey M.
Halim, Leena
Draper, Benjamin
Parente-Pereira, Ana C.
Zabinski, Tomasz
Davies, David Marc
Maher, John
author_sort Whilding, Lynsey M.
collection PubMed
description Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells against haematological malignancy, solid tumors impose a far greater challenge to success. Largely, this stems from an inadequate capacity of CAR T-cells that can traffic and maintain function within a hostile microenvironment. To enhance tumor-directed T-cell trafficking, we have engineered CAR T-cells to acquire heightened responsiveness to interleukin (IL)-8. Circulating IL-8 levels correlate with disease burden and prognosis in multiple solid tumors in which it exerts diverse pathological functions including angiogenesis, support of cancer stem cell survival, and recruitment of immunosuppressive myeloid cells. To harness tumor-derived IL-8 for therapeutic benefit, we have co-expressed either of its cognate receptors (CXCR1 or CXCR2) in CAR T-cells that target the tumor-associated αvβ6 integrin. We demonstrate here that CXCR2-expressing CAR T-cells migrate more efficiently towards IL-8 and towards tumor conditioned media that contains this cytokine. As a result, these CAR T-cells elicit superior anti-tumor activity against established αvβ6-expressing ovarian or pancreatic tumor xenografts, with a more favorable toxicity profile. These data support the further engineering of CAR T-cells to acquire responsiveness to cancer-derived chemokines in order to improve their therapeutic activity against solid tumors.
format Online
Article
Text
id pubmed-6563120
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65631202019-06-17 CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies Whilding, Lynsey M. Halim, Leena Draper, Benjamin Parente-Pereira, Ana C. Zabinski, Tomasz Davies, David Marc Maher, John Cancers (Basel) Article Despite the unprecedented clinical success of chimeric antigen receptors (CAR) T-cells against haematological malignancy, solid tumors impose a far greater challenge to success. Largely, this stems from an inadequate capacity of CAR T-cells that can traffic and maintain function within a hostile microenvironment. To enhance tumor-directed T-cell trafficking, we have engineered CAR T-cells to acquire heightened responsiveness to interleukin (IL)-8. Circulating IL-8 levels correlate with disease burden and prognosis in multiple solid tumors in which it exerts diverse pathological functions including angiogenesis, support of cancer stem cell survival, and recruitment of immunosuppressive myeloid cells. To harness tumor-derived IL-8 for therapeutic benefit, we have co-expressed either of its cognate receptors (CXCR1 or CXCR2) in CAR T-cells that target the tumor-associated αvβ6 integrin. We demonstrate here that CXCR2-expressing CAR T-cells migrate more efficiently towards IL-8 and towards tumor conditioned media that contains this cytokine. As a result, these CAR T-cells elicit superior anti-tumor activity against established αvβ6-expressing ovarian or pancreatic tumor xenografts, with a more favorable toxicity profile. These data support the further engineering of CAR T-cells to acquire responsiveness to cancer-derived chemokines in order to improve their therapeutic activity against solid tumors. MDPI 2019-05-14 /pmc/articles/PMC6563120/ /pubmed/31091832 http://dx.doi.org/10.3390/cancers11050674 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Whilding, Lynsey M.
Halim, Leena
Draper, Benjamin
Parente-Pereira, Ana C.
Zabinski, Tomasz
Davies, David Marc
Maher, John
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title_full CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title_fullStr CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title_full_unstemmed CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title_short CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies
title_sort car t-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor cxcr2 demonstrate enhanced homing and efficacy against several solid malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563120/
https://www.ncbi.nlm.nih.gov/pubmed/31091832
http://dx.doi.org/10.3390/cancers11050674
work_keys_str_mv AT whildinglynseym cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT halimleena cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT draperbenjamin cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT parentepereiraanac cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT zabinskitomasz cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT daviesdavidmarc cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies
AT maherjohn cartcellstargetingtheintegrinavb6andcoexpressingthechemokinereceptorcxcr2demonstrateenhancedhomingandefficacyagainstseveralsolidmalignancies